Author:
García-Villarreal Ovidio A
Reference8 articles.
1. FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery. [Access 08 May 2024] Available in: https://www.fda.gov/news-events/press-announcements/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-or-major
2. Kaneko T, Bapat VN, Alakhtar AM, et al. Transcatheter heart valve explantation for TAVR failure (TAVR-explant): a heart valve collaboratory expert consensus document on operative techniques. J Thorac Cardiovasc Surg 2024;S0022-5223(24)00369-6. doi: 10.1016/j.jtcvs.2024.04.025.
3. Tang GHL, Zaid S, Kleiman NS, et al. Explant vs redo-TAVR after transcatheter valve failure: mid-term outcomes from the EXPLANTORREDO-TAVR international registry. JACC Cardiovasc Interv. 2023;16(8):927-941. doi: 10.1016/j.jcin.2023.01.376.
4. Jacobs JP, Shahian DM, Grau-Sepulveda M, et al. Current penetration, completeness, and representativeness of The Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2022;113(5):1461-1468. doi: 10.1016/j.athoracsur.2021.04.107.
5. Bowdish ME, Habib RH, Kaneko T, Thourani VH, Badhwar V. Cardiac surgery after transcatheter aortic valve replacement: trends and outcomes. Ann Thorac Surg. 2024;S0003-4975(24)00254-6. doi: 10.1016/j.athoracsur.2024.03.024.